cardiovascular disease with obesity
Cardiovascular · 2025–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| semaglutide Secondary prevention of cardiovascular events in adults with established cardiovascular disease (prior myocardial infarction, stroke, or symptomatic peripheral… | Nov 2025 | Recommended with restriction | 89 individuals Health Consumer Council · Weight Issues Network · Heart Support Australia · National Aboriginal Community Controlled Health Organisation |
Who spoke
Health Consumer Council · Weight Issues Network · Heart Support Australia · National Aboriginal Community Controlled Health Organisation
What the PBS pays
$260M in government benefit over 2024–25, across 2,176,978 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| semaglutide | $260.5M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.